BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rössle M, Ochs A, Gülberg V, Siegerstetter V, Holl J, Deibert P, Olschewski M, Reiser M, Gerbes AL. A Comparison of Paracentesis and Transjugular Intrahepatic Portosystemic Shunting in Patients with Ascites. N Engl J Med 2000;342:1701-7. [DOI: 10.1056/nejm200006083422303] [Cited by in Crossref: 394] [Cited by in F6Publishing: 79] [Article Influence: 18.8] [Reference Citation Analysis]
Number Citing Articles
1 Van Thiel DH, Moore CM, Garcia M, George M, Nadir A. Continuous peritoneal drainage of large-volume ascites. Dig Dis Sci. 2011;56:2723-2727. [PMID: 21735084 DOI: 10.1007/s10620-011-1792-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
2 Siramolpiwat S. Transjugular intrahepatic portosystemic shunts and portal hypertension-related complications. World J Gastroenterol. 2014;20:16996-17010. [PMID: 25493012 DOI: 10.3748/wjg.v20.i45.16996] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 20] [Article Influence: 6.2] [Reference Citation Analysis]
3 Garcia-Tsao G. Transjugular intrahepatic portosystemic shunt in the management of refractory ascites. Semin Intervent Radiol 2005;22:278-86. [PMID: 21326706 DOI: 10.1055/s-2005-925554] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
4 Rössle M, Bausch B, Klinger C. Therapy Algorithm for Portal Vein Thrombosis in Liver Cirrhosis: The Internist's Point of View. Viszeralmedizin 2014;30:401-8. [PMID: 26288607 DOI: 10.1159/000370053] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
5 Mercadante S, Intravaia G, Ferrera P, Villari P, David F. Peritoneal catheter for continuous drainage of ascites in advanced cancer patients. Support Care Cancer 2008;16:975-8. [PMID: 18449571 DOI: 10.1007/s00520-008-0453-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
6 Hillebrand DJ. Spontaneous Bacterial Peritonitis. Curr Treat Options Gastroenterol. 2002;5:479-489. [PMID: 12408785 DOI: 10.1007/s11938-002-0036-8] [Reference Citation Analysis]
7 Annamalai A, Wisdom L, Herada M, Nourredin M, Ayoub W, Sundaram V, Klein A, Nissen N. Management of refractory ascites in cirrhosis: Are we out of date? World J Hepatol. 2016;8:1182-1193. [PMID: 27729954 DOI: 10.4254/wjh.v8.i28.1182] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
8 Thomas MN, Sauter GH, Gerbes AL, Stangl M, Schiergens TS, Angele M, Werner J, Guba M. Automated low flow pump system for the treatment of refractory ascites: a single-center experience. Langenbecks Arch Surg. 2015;400:979-983. [PMID: 26566989 DOI: 10.1007/s00423-015-1356-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
9 Tripathi D, Stanley AJ, Hayes PC, Travis S, Armstrong MJ, Tsochatzis EA, Rowe IA, Roslund N, Ireland H, Lomax M, Leithead JA, Mehrzad H, Aspinall RJ, McDonagh J, Patch D. Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension. Gut 2020;69:1173-92. [PMID: 32114503 DOI: 10.1136/gutjnl-2019-320221] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 22.0] [Reference Citation Analysis]
10 Seo JH, Kim SU, Park JY, Kim DY, Han KH, Chon CY, Ahn SH. Predictors of refractory ascites development in patients with hepatitis B virus-related cirrhosis hospitalized to control ascitic decompensation. Yonsei Med J 2013;54:145-53. [PMID: 23225811 DOI: 10.3349/ymj.2013.54.1.145] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
11 Aithal GP, Palaniyappan N, China L, Härmälä S, Macken L, Ryan JM, Wilkes EA, Moore K, Leithead JA, Hayes PC, O'Brien AJ, Verma S. Guidelines on the management of ascites in cirrhosis. Gut 2021;70:9-29. [PMID: 33067334 DOI: 10.1136/gutjnl-2020-321790] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 16.0] [Reference Citation Analysis]
12 Angermayr B, Cejna M, Karnel F, Gschwantler M, Koenig F, Pidlich J, Mendel H, Pichler L, Wichlas M, Kreil A, Schmid M, Ferlitsch A, Lipinski E, Brunner H, Lammer J, Ferenci P, Gangl A, Peck-Radosavljevic M. Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt. Gut. 2003;52:879-885. [PMID: 12740346 DOI: 10.1136/gut.52.6.879] [Cited by in Crossref: 188] [Cited by in F6Publishing: 167] [Article Influence: 10.4] [Reference Citation Analysis]
13 Zhao R, Lu J, Shi Y, Zhao H, Xu K, Sheng J. Current management of refractory ascites in patients with cirrhosis. J Int Med Res 2018;46:1138-45. [PMID: 29210304 DOI: 10.1177/0300060517735231] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
14 Mukerji AN, Patel V, Jain A. Improving survival in decompensated cirrhosis. Int J Hepatol. 2012;2012:318627. [PMID: 22811919 DOI: 10.1155/2012/318627] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
15 Narahara Y, Kanazawa H, Fukuda T, Matsushita Y, Harimoto H, Kidokoro H, Katakura T, Atsukawa M, Taki Y, Kimura Y, Nakatsuka K, Sakamoto C. Transjugular intrahepatic portosystemic shunt vs paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial. J Gastroenterol. 2011;46:78-85. [PMID: 20632194 DOI: 10.1007/s00535-010-0282-9] [Cited by in Crossref: 90] [Cited by in F6Publishing: 68] [Article Influence: 8.2] [Reference Citation Analysis]
16 Pedersen JS, Bendtsen F, Møller S. Management of cirrhotic ascites. Ther Adv Chronic Dis 2015;6:124-37. [PMID: 25954497 DOI: 10.1177/2040622315580069] [Cited by in Crossref: 28] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
17 Ditah IC, Al Bawardy BF, Saberi B, Ditah C, Kamath PS. Transjugular intrahepatic portosystemic stent shunt for medically refractory hepatic hydrothorax: A systematic review and cumulative meta-analysis. World J Hepatol. 2015;7:1797-1806. [PMID: 26167253 DOI: 10.4254/wjh.v7.i13.1797] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 4.7] [Reference Citation Analysis]
18 Moore KP, Aithal GP. Guidelines on the management of ascites in cirrhosis. Gut. 2006;55 Suppl 6:vi1-v12. [PMID: 16966752 DOI: 10.1136/gut.2006.099580] [Cited by in Crossref: 153] [Cited by in F6Publishing: 135] [Article Influence: 10.9] [Reference Citation Analysis]
19 Senousy BE, Draganov PV. Evaluation and management of patients with refractory ascites. World J Gastroenterol. 2009;15:67-80. [PMID: 19115470 DOI: 10.3748/wjg.15.67] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
20 Lenz K, Buder R, Kapun L, Voglmayr M. Treatment and management of ascites and hepatorenal syndrome: an update. Therap Adv Gastroenterol 2015;8:83-100. [PMID: 25729433 DOI: 10.1177/1756283X14564673] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
21 Lemmers A, Gustot T, Durnez A, Evrard S, Moreno C, Quertinmont E, Vercruysse V, Demetter P, Franchimont D, Le Moine O, Geerts A, Devière J. An inhibitor of interleukin-6 trans-signalling, sgp130, contributes to impaired acute phase response in human chronic liver disease. Clin Exp Immunol 2009;156:518-27. [PMID: 19438606 DOI: 10.1111/j.1365-2249.2009.03916.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
22 Garcia N, Sanyal AJ. Ascites. Curr Treat Options Gastroenterol. 2001;4:527-537. [PMID: 11696279 DOI: 10.1007/s11938-001-0018-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
23 Martens P, Nevens F. Budd-Chiari syndrome. United European Gastroenterol J. 2015;3:489-500. [PMID: 26668741 DOI: 10.1177/2050640615582293] [Cited by in Crossref: 47] [Cited by in F6Publishing: 20] [Article Influence: 7.8] [Reference Citation Analysis]
24 Moore CM, Van Thiel DH. Cirrhotic ascites review: Pathophysiology, diagnosis and management. World J Hepatol. 2013;5:251-263. [PMID: 23717736 DOI: 10.4254/wjh.v5.i5.251] [Cited by in Crossref: 56] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
25 García-Pagán JC, Saffo S, Mandorfer M, Garcia-Tsao G. Where does TIPS fit in the management of patients with cirrhosis? JHEP Rep 2020;2:100122. [PMID: 32671331 DOI: 10.1016/j.jhepr.2020.100122] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
26 Krajina A, Hulek P, Fejfar T, Valek V. Quality improvement guidelines for Transjugular Intrahepatic Portosystemic Shunt (TIPS). Cardiovasc Intervent Radiol. 2012;35:1295-1300. [PMID: 23070105 DOI: 10.1007/s00270-012-0493-y] [Cited by in Crossref: 44] [Cited by in F6Publishing: 30] [Article Influence: 4.9] [Reference Citation Analysis]
27 Patidar KR, Sydnor M, Sanyal AJ. Transjugular intrahepatic portosystemic shunt. Clin Liver Dis 2014;18:853-76. [PMID: 25438287 DOI: 10.1016/j.cld.2014.07.006] [Cited by in Crossref: 33] [Cited by in F6Publishing: 18] [Article Influence: 4.7] [Reference Citation Analysis]
28 Krajina A, Hulek P, Fejfar T, Valek V. Quality improvement guidelines for Transjugular Intrahepatic Portosystemic Shunt (TIPS). Cardiovasc Intervent Radiol. 2012;35:1295-1300. [PMID: 23070105 DOI: 10.1007/s00270-012-0493] [Reference Citation Analysis]
29 Mizrahi M, Roemi L, Shouval D, Adar T, Korem M, Moses A, Bloom A, Shibolet O. Bacteremia and “Endotipsitis” following transjugular intrahepatic portosystemic shunting. World J Hepatol. 2011;3:130-136. [PMID: 21731907 DOI: 10.4254/wjh.v3.i5.130] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
30 Schlenker C, Johnson S, Trotter JF. Preoperative transjugular intrahepatic portosystemic shunt (TIPS) for cirrhotic patients undergoing abdominal and pelvic surgeries. Surg Endosc. 2009;23:1594-1598. [PMID: 19263108 DOI: 10.1007/s00464-009-0405-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
31 Piano S, Tonon M, Angeli P. Management of ascites and hepatorenal syndrome. Hepatol Int 2018;12:122-34. [DOI: 10.1007/s12072-017-9815-0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 22] [Article Influence: 9.0] [Reference Citation Analysis]
32 Rosemurgy AS, Zervos EE, Clark WC, Thometz DP, Black TJ, Zwiebel BR, Kudryk BT, Grundy LS, Carey LC. TIPS versus peritoneovenous shunt in the treatment of medically intractable ascites: a prospective randomized trial. Ann Surg 2004;239:883-9; discussion 889-91. [PMID: 15166968 DOI: 10.1097/01.sla.0000128309.36393.71] [Cited by in Crossref: 42] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
33 Spengler EK, Hunsicker LG, Zarei S, Zimmerman MB, Voigt MD. Transjugular intrahepatic portosystemic shunt does not independently increase risk of death in high model for end stage liver disease patients. Hepatol Commun 2017;1:460-8. [PMID: 29404473 DOI: 10.1002/hep4.1053] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
34 Thuluvath PJ, Bal JS, Mitchell S, Lund G, Venbrux A. TIPS for management of refractory ascites: response and survival are both unpredictable. Dig Dis Sci 2003;48:542-50. [PMID: 12757168 DOI: 10.1023/a:1022544917898] [Cited by in Crossref: 28] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
35 Bandali MF, Mirakhur A, Lee EW, Ferris MC, Sadler DJ, Gray RR, Wong JK. Portal hypertension: Imaging of portosystemic collateral pathways and associated image-guided therapy. World J Gastroenterol. 2017;23:1735-1746. [PMID: 28348478 DOI: 10.3748/wjg.v23.i10.1735] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 15] [Article Influence: 8.5] [Reference Citation Analysis]
36 Thuluvath PJ, Bal JS, Mitchell S, Lund G, Venbrux A. TIPS for management of refractory ascites: response and survival are both unpredictable. Dig Dis Sci. 2003;48:542-550. [PMID: 12757168 DOI: 10.1023/A: 1022544917898] [Reference Citation Analysis]
37 Vassiliadis T, Garipidou V, Perifanis V, Tziomalos K, Giouleme O, Patsiaoura K, Avramidis M, Nikolaidis N, Vakalopoulou S, Tsitouridis I, Antoniadis A, Semertzidis P, Kioumi A, Premetis E, Eugenidis N. A case of successful management with splenectomy of intractable ascites due to congenital dyserythropoietic anemia type II-induced cirrhosis. World J Gastroenterol 2006;12:818-21. [PMID: 16521204 DOI: 10.3748/wjg.v12.i5.818] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
38 Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications. Clin Mol Hepatol 2018;24:230-77. [PMID: 29991196 DOI: 10.3350/cmh.2018.1005] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 8.3] [Reference Citation Analysis]
39 Stirnimann G, Berg T, Spahr L, Zeuzem S, McPherson S, Lammert F, Storni F, Banz V, Babatz J, Vargas V, Geier A, Stallmach A, Engelmann C, Trepte C, Capel J, De Gottardi A. Treatment of refractory ascites with an automated low-flow ascites pump in patients with cirrhosis. Aliment Pharmacol Ther. 2017;46:981-991. [PMID: 28940225 DOI: 10.1111/apt.14331] [Cited by in Crossref: 30] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
40 Sauerbruch T, Appenrodt B, Schmitz V, Spengler U. The conservative and interventional treatment of the complications of liver cirrhosis: Part 2 of a series on liver cirrhosis. Dtsch Arztebl Int 2013;110:126-32, I. [PMID: 23505400 DOI: 10.3238/arztebl.2013.0126] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
41 Lee JW, Hwang JS, Chung WJ, Lee HJ, Park JG, Lee CH, Kim BS, Song JE, Kweon YO, Tak WY, Park SY, Jang SY, Suh JI, Jang BK. Diagnostic usefulness of the spot urine sodium/potassium ratio in cirrhotic patients with ascites. PLoS One 2021;16:e0253886. [PMID: 34166456 DOI: 10.1371/journal.pone.0253886] [Reference Citation Analysis]
42 Maimone S, Saffioti F, Filomia R, Alibrandi A, Isgrò G, Calvaruso V, Xirouchakis E, Guerrini GP, Burroughs AK, Tsochatzis E, Patch D. Predictors of Re-bleeding and Mortality Among Patients with Refractory Variceal Bleeding Undergoing Salvage Transjugular Intrahepatic Portosystemic Shunt (TIPS). Dig Dis Sci 2019;64:1335-45. [PMID: 30560334 DOI: 10.1007/s10620-018-5412-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
43 Andring B, Kalva SP, Sutphin P, Srinivasa R, Anene A, Burrell M, Xi Y, Pillai AK. Effect of technical parameters on transjugular intrahepatic portosystemic shunts utilizing stent grafts. World J Gastroenterol. 2015;21:8110-8117. [PMID: 26185383 DOI: 10.3748/wjg.v21.i26.8110] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
44 Nusrat S, Khan MS, Fazili J, Madhoun MF. Cirrhosis and its complications: evidence based treatment. World J Gastroenterol. 2014;20:5442-5460. [PMID: 24833875 DOI: 10.3748/wjg.v20.i18.5442] [Cited by in CrossRef: 87] [Cited by in F6Publishing: 66] [Article Influence: 14.5] [Reference Citation Analysis]
45 Benmassaoud A, Freeman SC, Roccarina D, Plaz Torres MC, Sutton AJ, Cooper NJ, Iogna Prat L, Cowlin M, Milne EJ, Hawkins N, Davidson BR, Pavlov CS, Thorburn D, Tsochatzis E, Gurusamy KS. Treatment for ascites in adults with decompensated liver cirrhosis: a network meta-analysis. Cochrane Database Syst Rev 2020;1:CD013123. [PMID: 31978257 DOI: 10.1002/14651858.CD013123.pub2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
46 Horhat A, Bureau C, Thabut D, Rudler M. Transjugular intrahepatic portosystemic shunt in patients with cirrhosis: Indications and posttransjugular intrahepatic portosystemic shunt complications in 2020. United European Gastroenterol J 2021;9:203-8. [PMID: 32819214 DOI: 10.1177/2050640620952637] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Nicolas C, Le Gouge A, d'Alteroche L, Ayoub J, Georgescu M, Vidal V, Castaing D, Cercueil JP, Chevallier P, Roumy J, Trillaud H, Boyer L, Le Pennec V, Perret C, Giraudeau B, Perarnau JM, Stic-Tips Group. Evaluation of Doppler-ultrasonography in the diagnosis of transjugular intrahepatic portosystemic shunt dysfunction: A prospective study. World J Hepatol 2017;9:1125-32. [PMID: 29026464 DOI: 10.4254/wjh.v9.i27.1125] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
48 McCashland TM. Current use of transjugular intrahepatic portosystemic shunts. Curr Gastroenterol Rep. 2003;5:31-38. [PMID: 12530946 DOI: 10.1007/s11894-003-0007-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
49 Kim SK, Belikoff BG, Guevara CJ, Park SJ. An Algorithm for Management After Transjugular Intrahepatic Portosystemic Shunt Placement According to Clinical Manifestations. Dig Dis Sci. 2017;62:305-318. [PMID: 28058594 DOI: 10.1007/s10620-016-4399-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
50 Fanelli F. The Evolution of Transjugular Intrahepatic Portosystemic Shunt: Tips. ISRN Hepatol 2014;2014:762096. [PMID: 27335841 DOI: 10.1155/2014/762096] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
51 Nardelli S, Gioia S, Pasquale C, Pentassuglio I, Farcomeni A, Merli M, Salvatori FM, Nikolli L, Torrisi S, Greco F, Nicoletti V, Riggio O. Cognitive Impairment Predicts The Occurrence Of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt. Am J Gastroenterol. 2016;111:523-528. [PMID: 26925879 DOI: 10.1038/ajg.2016.29] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 5.6] [Reference Citation Analysis]
52 Harrison PM. Management of patients with decompensated cirrhosis. Clin Med (Lond) 2015;15:201-3. [PMID: 25824076 DOI: 10.7861/clinmedicine.15-2-201] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
53 Madan K, Mehta A. Management of renal failure and ascites in patients with cirrhosis. Int J Hepatol 2011;2011:790232. [PMID: 21994871 DOI: 10.4061/2011/790232] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
54 Schepke M, Sauerbruch T. Transjugular portosystemic stent shunt in treatment of liver diseases. World J Gastroenterol 2001;7:170-4. [PMID: 11819756 DOI: 10.3748/wjg.v7.i2.170] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
55 Angeli P, Morando F. Optimal management of hepatorenal syndrome in patients with cirrhosis. Hepat Med 2010;2:87-98. [PMID: 24367209 DOI: 10.2147/hmer.s6918] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
56 Pomier-Layrargues G, Bouchard L, Lafortune M, Bissonnette J, Guérette D, Perreault P. The transjugular intrahepatic portosystemic shunt in the treatment of portal hypertension: current status. Int J Hepatol. 2012;2012:167868. [DOI: 10.1155/2012/167868] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
57 Punamiya SJ, Amarapurkar DN. Role of TIPS in Improving Survival of Patients with Decompensated Liver Disease. Int J Hepatol 2011;2011:398291. [PMID: 21994854 DOI: 10.4061/2011/398291] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
58 Moller S, Henriksen JH, Bendtsen F. Pathogenetic background for treatment of ascites and hepatorenal syndrome. Hepatol Int. 2008;2:416-428. [PMID: 19669317 DOI: 10.1007/s12072-008-9100-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
59 Piecha F, Radunski UK, Ozga AK, Steins D, Drolz A, Horvatits T, Spink C, Ittrich H, Benten D, Lohse AW, Sinning C, Kluwe J. Ascites control by TIPS is more successful in patients with a lower paracentesis frequency and is associated with improved survival. JHEP Rep. 2019;1:90-98. [PMID: 32039356 DOI: 10.1016/j.jhepr.2019.04.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
60 Finkenstedt A, Graziadei IW, Nachbaur K, Jaschke W, Mark W, Margreiter R, Vogel W. Transjugular intrahepatic portosystemic shunt in liver transplant recipients. World J Gastroenterol 2009;15:1999-2004. [PMID: 19399933 DOI: 10.3748/wjg.15.1999] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
61 Bucher JN, Hollenbach M, Strocka S, Gaebelein G, Moche M, Kaiser T, Bartels M, Hoffmeister A. Segmental intrahepatic cholestasis as a technical complication of the transjugular intrahepatic porto-systemic shunt. World J Gastroenterol 2019;25:6430-9. [PMID: 31798279 DOI: 10.3748/wjg.v25.i43.6430] [Reference Citation Analysis]
62 Mumtaz K, Metwally S, Modi RM, Patel N, Tumin D, Michaels AJ, Hanje J, El-Hinnawi A, Hayes D Jr, Black SM. Impact of transjugular intrahepatic porto-systemic shunt on post liver transplantation outcomes: Study based on the United Network for Organ Sharing database. World J Hepatol 2017;9:99-105. [PMID: 28144391 DOI: 10.4254/wjh.v9.i2.99] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Fortune B, Cardenas A. Ascites, refractory ascites and hyponatremia in cirrhosis. Gastroenterol Rep (Oxf). 2017;5:104-112. [PMID: 28533908 DOI: 10.1093/gastro/gox010] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 7.5] [Reference Citation Analysis]
64 Allegretti AS, Ortiz G, Cui J, Wenger J, Bhan I, Chung RT, Thadhani RI, Irani Z. Changes in Kidney Function After Transjugular Intrahepatic Portosystemic Shunts Versus Large-Volume Paracentesis in Cirrhosis: A Matched Cohort Analysis. Am J Kidney Dis 2016;68:381-91. [PMID: 26994685 DOI: 10.1053/j.ajkd.2016.02.041] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 3.6] [Reference Citation Analysis]
65 Stadlbauer V, Tauss J, Portugaller HR, Stiegler P, Iberer F, Stauber RE. Hepatic encephalopathy following transjugular intrahepatic portosystemic shunt (TIPS): management with L-ornithine-L-aspartate and stent reduction. Metab Brain Dis. 2007;22:45-50. [PMID: 17165154 DOI: 10.1007/s11011-006-9032-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
66 Riggio O, Nardelli S, Pasquale C, Pentassuglio I, Gioia S, Onori E, Frieri C, Salvatori FM, Merli M. No effect of albumin infusion on the prevention of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Metab Brain Dis. 2016;31:1275-1281. [PMID: 26290375 DOI: 10.1007/s11011-015-9713-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
67 Guan R, Lui HF. Treatment of hepatitis B in decompensated liver cirrhosis. Int J Hepatol. 2011;2011:918017. [PMID: 21994876 DOI: 10.4061/2011/918017] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
68 Peck-Radosavljevic M, Angeli P, Cordoba J, Farges O, Valla D. Managing complications in cirrhotic patients. United European Gastroenterol J 2015;3:80-94. [PMID: 25653862 DOI: 10.1177/2050640614560452] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
69 Caly WR, Abreu RM, Bitelman B, Carrilho FJ, Ono SK. Clinical Features of Refractory Ascites in Outpatients. Clinics (Sao Paulo). 2017;72:405-410. [PMID: 28792999 DOI: 10.6061/clinics/2017(07)03] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
70 Rajesh S, George T, Philips CA, Ahamed R, Kumbar S, Mohan N, Mohanan M, Augustine P. Transjugular intrahepatic portosystemic shunt in cirrhosis: An exhaustive critical update.World J Gastroenterol. 2020;26:5561-5596. [PMID: 33088154 DOI: 10.3748/wjg.v26.i37.5561] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
71 Biecker E. Diagnosis and therapy of ascites in liver cirrhosis. World J Gastroenterol 2011;17:1237-48. [PMID: 21455322 DOI: 10.3748/wjg.v17.i10.1237] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 28] [Article Influence: 4.6] [Reference Citation Analysis]
72 Gallo A, Dedionigi C, Civitelli C, Panzeri A, Corradi C, Squizzato A. Optimal Management of Cirrhotic Ascites: A Review for Internal Medicine Physicians. J Transl Int Med 2020;8:220-36. [PMID: 33511049 DOI: 10.2478/jtim-2020-0035] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Bhogal HK, Sanyal AJ. Using transjugular intrahepatic portosystemic shunts for complications of cirrhosis. Clin Gastroenterol Hepatol. 2011;9:936-946; quiz e123. [PMID: 21699820 DOI: 10.1016/j.cgh.2011.06.013] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
74 Bai M, Qi XS, Yang ZP, Yang M, Fan DM, Han GH. TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: an updated meta-analysis. World J Gastroenterol. 2014;20:2704-2714. [PMID: 24627607 DOI: 10.3748/wjg.v20.i10.2704] [Cited by in CrossRef: 62] [Cited by in F6Publishing: 43] [Article Influence: 10.3] [Reference Citation Analysis]
75 Wallace MJ, Madoff DC. Transjugular intrahepatic portosystemic shunts in patients with hepatic malignancy. Semin Intervent Radiol. 2005;22:309-315. [PMID: 21326709 DOI: 10.1055/s-2005-925557] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
76 Gerbes AL, Gulberg V. Progress in treatment of massive ascites and hepatorenal syndrome. World J Gastroenterol. 2006;12:516-519. [PMID: 16489662 DOI: 10.3748/wjg.v12.i4.516] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
77 Stirnimann G, Banz V, Storni F, De Gottardi A. Automated low-flow ascites pump for the treatment of cirrhotic patients with refractory ascites. Therap Adv Gastroenterol. 2017;10:283-292. [PMID: 28203285 DOI: 10.1177/1756283x16684688] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
78 Qi XS, Bai M, Yang ZP, Fan DM. Selection of a TIPS stent for management of portal hypertension in liver cirrhosis: an evidence-based review. World J Gastroenterol. 2014;20:6470-6480. [PMID: 24914368 DOI: 10.3748/wjg.v20.i21.6470] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
79 Møller S, Henriksen JH. Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease. Heart 2002;87:9-15. [PMID: 11751653 DOI: 10.1136/heart.87.1.9] [Cited by in Crossref: 202] [Cited by in F6Publishing: 181] [Article Influence: 10.6] [Reference Citation Analysis]